MedTrace Logo

Fludeoxyglucose F 18 PET Imaging in Determining Protein and Gene Expression Signatures in Patients With Premalignant Polyps or Colon Cancer

NCT00550628 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 8

Last updated 2015-12-23

No results posted yet for this study

Summary

RATIONALE: Diagnostic imaging procedures, such as fludeoxyglucose F 18 PET, may be effective in detecting cancer or recurrence of cancer, or premalignant polyps.

PURPOSE: This clinical trial is studying fludeoxyglucose F 18-PET imaging to see how well it works in determining protein and gene expression signatures in patients with premalignant polyps or colon cancer.

Conditions

Interventions

GENETIC

DNA methylation analysis

GENETIC

fluorescence in situ hybridization

GENETIC

gene expression analysis

GENETIC

polymerase chain reaction

GENETIC

protein expression analysis

GENETIC

reverse transcriptase-polymerase chain reaction

OTHER

diagnostic laboratory biomarker analysis

OTHER

immunoenzyme technique

OTHER

immunohistochemistry staining method

PROCEDURE

biopsy

PROCEDURE

therapeutic conventional surgery

RADIATION

fludeoxyglucose F 18

Sponsors & Collaborators

Principal Investigators

  • Marc J. Gollub, MD · Memorial Sloan Kettering Cancer Center

  • Suresh Jhanwar, PhD · Memorial Sloan Kettering Cancer Center

Eligibility

Min Age
15 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-09-30
Primary Completion
2011-09-30
Completion
2011-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00550628 on ClinicalTrials.gov